EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer

Xingbin Hu, Zhenfeng Ma, Beibei Xu, Shulong Li, Zhiqi Yao, Bishan Liang, Jiao Wang, Wangjun Liao iD, Li Lin, Chunling Wang, Siting Zheng, Qijing Wu und 4 weitere

Cancer Communications · 2023-08 · 43 (8) · 909-937

DOI: 10.1002/cac2.12459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 11.07.2023. Verfasst von Xingbin Hu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China. Hauptthemen laut MEDLINE: Glutamine, Stomach Neoplasms. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab is a first‐line targeted therapy for human epidermal growth factor receptor‐2 (HER2)‐positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there is currently no effective reversal measure. Existing researches on the mechanism of trastuzumab resistance mainly focused on tumor cells themselves, while the understanding of the mechanisms of environment‐mediated drug resistance is relatively lacking. This study aimed to further explore the mechanisms of trastuzumab resistance to identify strategies to promote survival in these patients.

Methods

Trastuzumab‐sensitive and trastuzumab‐resistant HER2‐positive tumor tissues and cells were collected for transcriptome sequencing. Bioinformatics were used to analyze cell subtypes, metabolic pathways, and molecular signaling pathways. Changes in microenvironmental indicators (such as macrophage, angiogenesis, and metabolism) were verified by immunofluorescence (IF) and immunohistochemical (IHC) analyses. Finally, a multi‐scale agent‐based model (ABM) was constructed. The effects of combination treatment were further validated in nude mice to verify these effects predicted by the ABM.

Results

Based on transcriptome sequencing, molecular biology, and in vivo experiments, we found that the level of glutamine metabolism in trastuzumab‐resistant HER2‐positive cells was increased, and glutaminase 1 (GLS1) was significantly overexpressed. Meanwhile, tumor‐derived GLS1 microvesicles drove M2 macrophage polarization. Furthermore, angiogenesis promoted trastuzumab resistance. IHC showed high glutamine metabolism, M2 macrophage polarization, and angiogenesis in trastuzumab‐resistant HER2‐positive tumor tissues from patients and nude mice. Mechanistically, the cell division cycle 42 (CDC42) promoted GLS1 expression in tumor cells by activating nuclear factor kappa‐B (NF‐κB) p65 and drove GLS1 microvesicle secretion through IQ motif‐containing GTPase‐activating protein 1 (IQGAP1). Based on the ABM and in vivo experiments, we confirmed that the combination of anti‐glutamine metabolism, anti‐angiogenesis, and pro‐M1 polarization therapy had the best effect in reversing trastuzumab resistance in HER2‐positive gastric cancer.

Conclusions

This study revealed that tumor cells secrete GLS1 microvesicles via CDC42 to promote glutamine metabolism, M2 macrophage polarization, and pro‐angiogenic function of macrophages, leading to acquired trastuzumab resistance in HER2‐positive gastric cancer. A combination of anti‐glutamine metabolism, anti‐angiogenesis, and pro‐M1 polarization therapy may provide a new insight into reversing trastuzumab resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutamineStomach NeoplasmsAnimalsMiceHumansTrastuzumabMice, NudeDrug Resistance, NeoplasmMacrophagesTumor Microenvironment

Stichwörter der Autor:innen

Gastric cancerglutamine metabolismmacrophagemathematical modelmicrovesiclestrastuzumab

Substanzen

TrastuzumabGlutamine

Autor:innen und Institutionen

  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.

ORCID-Profile: Wangjun Liao, Fenghua Wang, Min Shi

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, X., Ma, Z., Xu, B., Li, S., Yao, Z., Liang, B., Wang, J., Liao, W., Lin, L., Wang, C., Zheng, S., Wu, Q., Huang, Q., Yu, L., Wang, F., & Shi, M. (2023). Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer. Cancer Communications, 43(8), 909-937. https://doi.org/10.1002/cac2.12459

Vancouver

Hu X, Ma Z, Xu B, Li S, Yao Z, Liang B, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer. Cancer Communications. 2023;43(8):909-937. doi:10.1002/cac2.12459

BibTeX
@article{Hu2023,
  author = {Hu, Xingbin and Ma, Zhenfeng and Xu, Beibei and Li, Shulong and Yao, Zhiqi and Liang, Bishan and Wang, Jiao and Liao, Wangjun and Lin, Li and Wang, Chunling and Zheng, Siting and Wu, Qijing and Huang, Qiong and Yu, Le and Wang, Fenghua and Shi, Min},
  title = {Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer},
  journal = {Cancer Communications},
  year = {2023},
  volume = {43},
  number = {8},
  pages = {909--937},
  doi = {10.1002/cac2.12459}
}
Kostenlos starten →